Sai Life Sciences Fully Utilizes Rs 9,500 Million IPO Fresh Proceeds
Sai Life Sciences Ltd 路 Others (Uncategorized) 路 12 Nov 2026, 4:36 pm
Sai Life Sciences Fully Utilizes Rs 9,500 Million IPO Fresh Proceeds CRISIL Ratings released the final monitoring agency report for Sai Life Sciences Ltd for the quarter ended 30th Sep'26, confirming 100% utilization of its Rs 9,500.00 million gross IPO fresh issue proceeds. Allocations included Rs 7,200.00 million toward debt repayment, Rs 380.73 million for issue expenses, and Rs 1,919.27 million for general corporate purposes, including Rs 20.43 million deployed for equipment and machinery during the quarter following savings in issue expenses. Monitoring account balances stand at nil with zero deviations.
Original exchange filing (PDF)
More announcements from Sai Life Sciences Ltd
- Upgradation in the Credit Rating by India Rating & Research Pvt. Ltd. 路 14 Nov 2026
- Transcripts of Earnings call organized on 06th November 2026 路 12 Nov 2026
- Audio Recording of Earnings call for Q-2 FY 2026-27 路 06 Nov 2026
- Investor Presentation on Q-2 FY 2026-27 Financial Results 路 06 Nov 2026
- Press Release on Unaudited Financial Results for the Second Quarter and Half Year Ended 30th September 2026. 路 06 Nov 2026
- Allotment of 1,08,005 Equity having Face Value of Rs.1/- against the options exercised in accordance with the Companies ESOP Plans 路 06 Nov 2026
- Sai Life Sciences Limited has informed the Exchange regarding Allotment of 108005 Shares. 路 06 Nov 2026
- Change In Management - Appointment of SMPs 路 06 Nov 2026
